The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
Abstract
The 2;5 chromosomal translocation occurs in most anaplastic large-cell non-Hodgkin's lymphomas arising from activated T lymphocytes. This rearrangement was shown to fuse the NPM nucleolar phosphoprotein gene on chromosome 5q35 to a previously unidentified protein tyrosine kinase gene, ALK , on chromosome 2p23. In the predicted hybrid protein, the amino terminus of nucleophosmin (NPM) is linked to the catalytic domain of anaplastic lymphoma kinase (ALK). Expressed in the small intestine, testis, and brain but not in normal lymphoid cells, ALK shows greatest sequence similarity to the insulin receptor subfamily of kinases. Unscheduled expression of the truncated ALK may contribute to malignant transformation in these lymphomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Protein Kinase Family: Conserved Features and Deduced Phylogeny of the Catalytic Domains
Hanks, S. K., Quinn, A. M., & Hunter, T. (1988) · Science · doi:10.1126/science.3291115 · Cited by 5,039
Interleukin-2: Inception, Impact, and Implications
Smith, K. A. (1988) · Science · doi:10.1126/science.3131876 · Cited by 2,153
Growth factor signaling by receptor tyrosine kinases
Schlessinger, J., & Ullrich, A. (1992) · Neuron · doi:10.1016/0896-6273(92)90177-f · Cited by 1,430
Major nucleolar proteins shuttle between nucleus and cytoplasm
Borer, R. A., Lehner, C. F., Eppenberger, H. M., & Nigg, E. A. (1989) · Cell · doi:10.1016/0092-8674(89)90241-9 · Cited by 1,114
Dürkop, H., Latza, U., Hummel, M., Eitelbach, F., Seed, B., & Stein, H. (1992) · Cell · doi:10.1016/0092-8674(92)90180-k · Cited by 643
Smith, C. A., Gruss, H.-J., Davis, T., Anderson, D., Farrah, T., Baker, E., Sutherland, G. R., Brannan, C. I., Copeland, N. G., Jenkins, N. A., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90361-s · Cited by 529
T cell antigen receptor activation pathways: The tyrosine kinase connection
Klausner, R. D., & Samelson, L. E. (1991) · Cell · doi:10.1016/0092-8674(91)90310-u · Cited by 428
Chan, W. Y., Liu, Q. R., Borjigin, J., Busch, H., Rennert, O. M., Tease, L. A., & Chan, P. K. (1989) · Biochemistry · doi:10.1021/bi00429a017 · Cited by 270
Interphase and Metaphase Resolution of Different Distances Within the Human Dystrophin Gene
Lawrence, J. B., Singer, R. H., & McNeil, J. A. (1990) · Science · doi:10.1126/science.2203143 · Cited by 257
Brinkman, A., Groffen, C., Kortleve, D. J., Geurts van Kessel, A., & Drop, S. L. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb03087.x · Cited by 247
Cited by
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Chromosomal translocations in human cancer
Rabbitts, T. H. (1994) · Nature · doi:10.1038/372143a0 · Cited by 1,503
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
Identification of ALK as a major familial neuroblastoma predisposition gene
Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, P., et al. (2008) · Nature · doi:10.1038/nature07261 · Cited by 1,407
Armitage, J. O., Gascoyne, R. D., Lunning, M. A., & Cavalli, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32407-2 · Cited by 1,176
Golub, T. R., Barker, G. F., Lovett, M., & Gilliland, D. G. (1994) · Cell · doi:10.1016/0092-8674(94)90322-0 · Cited by 1,155
Immunoaffinity profiling of tyrosine phosphorylation in cancer cells
Rush, J., Moritz, A., Lee, K. A., Guo, A., Goss, V. L., Spek, E. J., Zhang, H., Zha, X.-M., Polakiewicz, R. D., & Comb, M. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1046 · Cited by 1,124
Mechanisms of receptor tyrosine kinase activation in cancer
Du, Z., & Lovly, C. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0782-4 · Cited by 1,066
Doebele, R. C., Pilling, A. B., Aisner, D. L., Kutateladze, T. G., Le, A. T., Weickhardt, A. J., Kondo, K. L., Linderman, D. J., Heasley, L. E., Franklin, W. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2906 · Cited by 1,063
Melnick, A., & Licht, J. D. (1999) · Blood · doi:10.1182/blood.v93.10.3167.410k44_3167_3215 · Cited by 1,028
Coffin, C. M., Hornick, J. L., & Fletcher, C. D. M. (2007) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213393.57322.c7 · Cited by 1,006
EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
Koivunen, J. P., Mermel, C., Zejnullahu, K., Murphy, C., Lifshits, E., Holmes, A. J., Choi, H. G., Kim, J., Chiang, D., Thomas, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0168 · Cited by 993
Understanding and targeting resistance mechanisms in NSCLC
Rotow, J., & Bivona, T. G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.84 · Cited by 972
Cui, J. J., Tran-Dubé, M., Shen, H., Nambu, M., Kung, P.-P., Pairish, M., Jia, L., Meng, J., Funk, L., Botrous, I., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2007613 · Cited by 932
Oncogenic mutations of ALK kinase in neuroblastoma
Chen, Y., Takita, J., Choi, Y. L., Kato, M., Ohira, M., Sanada, M., Wang, L., Soda, M., Kikuchi, A., Igarashi, T., et al. (2008) · Nature · doi:10.1038/nature07399 · Cited by 916
Shaw, A. T., Yeap, B. Y., Solomon, B. J., Riely, G. J., Gainor, J., Engelman, J. A., Shapiro, G. I., Costa, D. B., Ou, S.-H. I., Butaney, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70232-7 · Cited by 899
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Janoueix-Lerosey, I., Lequin, D., Brugières, L., Ribeiro, A., de Pontual, L., Combaret, V., Raynal, V., Puisieux, A., Schleiermacher, G., Pierron, G., et al. (2008) · Nature · doi:10.1038/nature07398 · Cited by 894
Activating mutations in ALK provide a therapeutic target in neuroblastoma
George, R. E., Sanda, T., Hanna, M., Fröhling, S., II, W. L., Zhang, J., Ahn, Y., Zhou, W., London, W. B., McGrady, P., et al. (2008) · Nature · doi:10.1038/nature07397 · Cited by 893
Self-citationThe anaplastic lymphoma kinase in the pathogenesis of cancer
Chiarle, R., Voena, C., Ambrogio, C., Piva, R., & Inghirami, G. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2291 · Cited by 882
Savage, K. J., Harris, N. L., Vose, J. M., Ullrich, F., Jaffe, E. S., Connors, J. M., Rimsza, L., Pileri, S. A., Chhanabhai, M., Gascoyne, R. D., et al. (2008) · Blood · doi:10.1182/blood-2008-01-134270 · Cited by 863
Grisendi, S., Mecucci, C., Falini, B., & Pandolfi, P. P. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1885 · Cited by 850
Döhner, K., Schlenk, R. F., Habdank, M., Scholl, C., Rücker, F. G., Corbacioglu, A., Bullinger, L., Fröhling, S., Döhner, H., & for the AML Study Group (AMLSG) (2005) · Blood · doi:10.1182/blood-2005-05-2164 · Cited by 849
New driver mutations in non-small-cell lung cancer
Tanoue, L. T. (2012) · Yearbook of Pulmonary Disease · doi:10.1016/j.ypdi.2012.01.036 · Cited by 831
Impact of Protein Kinase PKR in Cell Biology: from Antiviral to Antiproliferative Action
García, M. A., Gil, J., Ventoso, I., Guerra, S., Domingo, E., Rivas, C., & Esteban, M. (2006) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00027-06 · Cited by 818
Marzec, M., Zhang, Q., Goradia, A., Raghunath, P. N., Liu, X., Paessler, M., Wang, H. Y., Wysocka, M., Cheng, M., Ruggeri, B. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810958105 · Cited by 728
Takeuchi, K., Choi, Y. L., Togashi, Y., Soda, M., Hatano, S., Inamura, K., Takada, S., Ueno, T., Yamashita, Y., Satoh, Y., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3248 · Cited by 717
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
(2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.05.01 · Cited by 716
TPM3-ALK and TPM4-ALK Oncogenes in Inflammatory Myofibroblastic Tumors
Lawrence, B., Perez-Atayde, A., Hibbard, M. K., Rubin, B. P., Dal Cin, P., Pinkus, J. L., Pinkus, G. S., Xiao, S., Yi, E. S., Fletcher, C. D. M., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64550-6 · Cited by 714
Mossé, Y. P., Lim, M. S., Voss, S. D., Wilner, K., Ruffner, K., Laliberte, J., Rolland, D., Balis, F. M., Maris, J. M., Weigel, B. J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70095-0 · Cited by 712
Rodig, S. J., Mino-Kenudson, M., Dacic, S., Yeap, B. Y., Shaw, A., Barletta, J. A., Stubbs, H., Law, K., Lindeman, N., Mark, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0802 · Cited by 678
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
Hallberg, B., & Palmer, R. H. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3580 · Cited by 645
In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system
Maddalo, D., Manchado, E., Concepcion, C. P., Bonetti, C., Vidigal, J. A., Han, Y.-C., Ogrodowski, P., Crippa, A., Rekhtman, N., de Stanchina, E., et al. (2014) · Nature · doi:10.1038/nature13902 · Cited by 640
CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
Sakamoto, H., Tsukaguchi, T., Hiroshima, S., Kodama, T., Kobayashi, T., Fukami, T. A., Oikawa, N., Tsukuda, T., Ishii, N., & Aoki, Y. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.004 · Cited by 636
Verhaak, R. G. W., Goudswaard, C. S., van Putten, W., Bijl, M. A., Sanders, M. A., Hugens, W., Uitterlinden, A. G., Erpelinck, C. A. J., Delwel, R., Löwenberg, B., et al. (2005) · Blood · doi:10.1182/blood-2005-05-2168 · Cited by 618
PROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 613
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
Sasaki, T., Koivunen, J., Ogino, A., Yanagita, M., Nikiforow, S., Zheng, W., Lathan, C., Marcoux, J. P., Du, J., Okuda, K., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1340 · Cited by 597
Johnson, T. W., Richardson, P. F., Bailey, S., Brooun, A., Burke, B. J., Collins, M. R., Cui, J. J., Deal, J. G., Deng, Y.-L., Dinh, D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500261q · Cited by 594
Seto, T., Kiura, K., Nishio, M., Nakagawa, K., Maemondo, M., Inoue, A., Hida, T., Yamamoto, N., Yoshioka, H., Harada, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70142-6 · Cited by 575
Falini, B., Nicoletti, I., Martelli, M. F., & Mecucci, C. (2007) · Blood · doi:10.1182/blood-2006-07-012252 · Cited by 565
Role of nucleophosmin in embryonic development and tumorigenesis
Grisendi, S., Bernardi, R., Rossi, M., Cheng, K., Khandker, L., Manova, K., & Pandolfi, P. P. (2005) · Nature · doi:10.1038/nature03915 · Cited by 561
ALK+ lymphoma: clinico-pathological findings and outcome.
Falini, B., Pileri, S. A., Zinzani, P. L., Carbone, A., Zagonel, V., Wolf‐Peeters, C. D., Verhoef, G. E. G., Menestrina, F., Todeschini, G., Paulli, M., et al. (1999) · PubMed · doi:10.1182/blood.v93.8.2697 · Cited by 560
Mrózek, K., Marcucci, G., Paschka, P., Whitman, S. P., & Bloomfield, C. D. (2007) · Blood · doi:10.1182/blood-2006-06-001149 · Cited by 552
Hunter, T. (1997) · Cell · doi:10.1016/s0092-8674(00)81872-3 · Cited by 550
Nucleophosmin regulates the stability and transcriptional activity of p53
Colombo, E., Marine, J.-C., Danovi, D., Falini, B., & Pelicci, P. G. (2002) · Nature Cell Biology · doi:10.1038/ncb814 · Cited by 528
Gascoyne, R. D., Aoun, P., Wu, D., Chhanabhai, M., Skinnider, B. F., Greiner, T. C., Morris, S. W., Connors, J. M., Vose, J. M., Viswanatha, D. S., et al. (1999) · Blood · doi:10.1182/blood.v93.11.3913 · Cited by 524
Self-citationTargeting ALK: Precision Medicine Takes on Drug Resistance
Lin, J. J., Riely, G. J., & Shaw, A. T. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1123 · Cited by 522
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Cooper, A. J., Sequist, L. V., & Lin, J. J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00639-9 · Cited by 508
EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers
Inamura, K., Takeuchi, K., Togashi, Y., Nomura, K., Ninomiya, H., Okui, M., Satoh, Y., Okumura, S., Nakagawa, K., Soda, M., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31815e8b60 · Cited by 467
ALK in Lung Cancer: Past, Present, and Future
Shaw, A. T., & Engelman, J. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.5353 · Cited by 461
Non-Hodgkin's Lymphoma in Childhood
Sandlund, J. T., Downing, J. R., & Crist, W. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605093341906 · Cited by 443
Redner, R., Rush, E., Faas, S., Rudert, W., & Corey, S. (1996) · Blood · doi:10.1182/blood.v87.3.882.bloodjournal873882 · Cited by 442
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target
Chiarle, R., Simmons, W. J., Cai, H., Dhall, G., Zamo, A., Raz, R., Karras, J. G., Levy, D. E., & Inghirami, G. (2005) · Nature Medicine · doi:10.1038/nm1249 · Cited by 442
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
Sharma, S. V., & Settleman, J. (2007) · Genes & Development · doi:10.1101/gad.1609907 · Cited by 441
Falini, B., Pileri, S., Pizzolo, G., Durkop, H., Flenghi, L., Stirpe, F., Martelli, M., & Stein, H. (1995) · Blood · doi:10.1182/blood.v85.1.1.bloodjournal8511 · Cited by 441
Anaplastic lymphoma kinase: signalling in development and disease
Palmer, R. H., Vernersson, E., Grabbe, C., & Hallberg, B. (2009) · Biochemical Journal · doi:10.1042/bj20090387 · Cited by 423
Marsilje, T. H., Pei, W., Chen, B., Lu, W., Uno, T., Jin, Y., Jiang, T., Kim, S., Li, N., Warmuth, M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400402q · Cited by 418
Mossé, Y. P., Voss, S. D., Lim, M. S., Rolland, D., Minard, C. G., Fox, E., Adamson, P., Wilner, K., Blaney, S. M., & Weigel, B. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.4830 · Cited by 413
Huang, W.-S., Liu, S., Zou, D., Thomas, M., Wang, Y., Zhou, T., Romero, J., Kohlmann, A., Li, F., Qi, J., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00306 · Cited by 412
Hunter, T. (1998) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.1998.0228 · Cited by 410
Retinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death
Zamo, A., Chiarle, R., Piva, R., Howes, J., Fan, Y., Chilosi, M., Levy, D. E., & Inghirami, G. (2002) · Oncogene · doi:10.1038/sj.onc.1205152 · Cited by 399
McDermott, U., Iafrate, A. J., Gray, N. S., Shioda, T., Classon, M., Maheswaran, S., Zhou, W., Choi, H. G., Smith, S. L., Dowell, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6186 · Cited by 399
Iqbal, J., Weisenburger, D. D., Greiner, T. C., Vose, J. M., McKeithan, T., Kucuk, C., Geng, H., Deffenbacher, K., Smith, L., Dybkaer, K., et al. (2010) · Blood · doi:10.1182/blood-2009-06-227579 · Cited by 392
Mariño-Enríquez, A., Wang, W.-L., Roy, A., Lopez-Terrada, D., Lazar, A. J. F., Fletcher, C. D. M., Coffin, C. M., & Hornick, J. L. (2011) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318200cfd5 · Cited by 389
Bresler, S. C., Weiser, D. A., Huwe, P. J., Park, J. H., Krytska, K., Ryles, H., Laudenslager, M., Rappaport, E. F., Wood, A. C., McGrady, P. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.019 · Cited by 388
Walker, A. J., Majzner, R. G., Zhang, L., Wanhainen, K., Long, A. H., Nguyen, S. M., Lopomo, P., Vigny, M., Fry, T. J., Orentas, R. J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.06.008 · Cited by 383
Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin
Stoica, G. E., Kuo, A., Aigner, A., Sunitha, I., Souttou, B., Malerczyk, C., Caughey, D. J., Wen, D., Karavanov, A., Riegel, A. T., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010660200 · Cited by 382
Antonescu, C. R., Suurmeijer, A. J. H., Zhang, L., Sung, Y.-S., Jungbluth, A. A., Travis, W. D., Al-Ahmadie, H., Fletcher, C. D. M., & Alaggio, R. (2015) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000404 · Cited by 381
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
Galkin, A. V., Melnick, J. S., Kim, S., Hood, T. L., Li, N., Li, L., Xia, G., Steensma, R., Chopiuk, G., Jiang, J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609412103 · Cited by 379
The role of the ALK receptor in cancer biology
Hallberg, B., & Palmer, R. H. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw301 · Cited by 377
A directed screen for genes involved in Drosophila blood cell activation
Zettervall, C.-J., Anderl, I., Williams, M. J., Palmer, R., Kurucz, E., Ando, I., & Hultmark, D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403789101 · Cited by 366
Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis
Zhu, S., Lee, J.-S., Guo, F., Shin, J., Perez-Atayde, A. R., Kutok, J. L., Rodig, S. J., Neuberg, D. S., Helman, D., Feng, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.010 · Cited by 365
Self-citationSavage, K. J., Chhanabhai, M., Gascoyne, R. D., & Connors, J. M. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh392 · Cited by 363
Bischof, D., Pulford, K., Mason, D. Y., & Morris, S. W. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.4.2312 · Cited by 363
Self-citationFusion of the ALK Gene to the Clathrin Heavy Chain Gene, CLTC, in Inflammatory Myofibroblastic Tumor
Bridge, J. A., Kanamori, M., Ma, Z., Pickering, D., Hill, D. A., Lydiatt, W., Lui, M. Y., Colleoni, G. W. B., Antonescu, C. R., Ladanyi, M., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61711-7 · Cited by 359
Self-citationCooperating gene mutations in acute myeloid leukemia: a review of the literature
Renneville, A., Roumier, C., Biggio, V, Nibourel, O., Boissel, N., Fenaux, P., & Preudhomme, C. (2008) · Leukemia · doi:10.1038/leu.2008.19 · Cited by 351
Solomon, B., Varella-Garcia, M., & Camidge, D. R. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181c4dedb · Cited by 343
Bourgeois, J. M., Knezevich, S. R., Mathers, J. A., & Sorensen, P. H. B. (2000) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200007000-00005 · Cited by 338
Sasaki, T., Okuda, K., Zheng, W., Butrynski, J., Capelletti, M., Wang, L., Gray, N. S., Wilner, K., Christensen, J. G., Demetri, G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2956 · Cited by 335
Sequist, L. V., Gettinger, S., Senzer, N. N., Martins, R. G., Jänne, P. A., Lilenbaum, R., Gray, J. E., Iafrate, A. J., Katayama, R., Hafeez, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8338 · Cited by 330
Meis1, a PBX1-Related Homeobox Gene Involved in Myeloid Leukemia in BXH-2 Mice
Moskow, J. J., Bullrich, F., Huebner, K., Daar, I. O., & Buchberg, A. M. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.10.5434 · Cited by 328
Targeted protein degradation: advances in drug discovery and clinical practice
Zhong, G., Chang, X., Xie, W., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02004-x · Cited by 326
Grimwade, D. J., Biondi, A., Mozziconacci, J., Hagemeijer, A., Berger, R., Neat, M. J., Howe, K. M., Dastugue, N., Jansen, J. H., Radford‐Weiss, I., et al. (2000) · PubMed · doi:10.1182/blood.v96.4.1297 · Cited by 325
Ardini, E., Menichincheri, M., Banfi, P., Bosotti, R., De Ponti, C., Pulci, R., Ballinari, D., Ciomei, M., Texido, G., Degrassi, A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0758 · Cited by 321
Bai, R.-Y., Ouyang, T., Miething, C., Morris, S. W., Peschel, C., & Duyster, J. (2000) · Blood · doi:10.1182/blood.v96.13.4319 · Cited by 319
Self-citationEML4-ALK: Honing In on a New Target in Non–Small-Cell Lung Cancer
Horn, L., & Pao, W. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6661 · Cited by 319
EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues
Martelli, M. P., Sozzi, G., Hernandez, L., Pettirossi, V., Navarro, A., Conte, D., Gasparini, P., Perrone, F., Modena, P., Pastorino, U., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080755 · Cited by 317
Targeting Anaplastic Lymphoma Kinase in Lung Cancer
Shaw, A. T., & Solomon, B. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1591 · Cited by 308
Validating Stat3 in cancer therapy
Darnell, J. E. (2005) · Nature Medicine · doi:10.1038/nm0605-595 · Cited by 307
NPM1/B23: A Multifunctional Chaperone in Ribosome Biogenesis and Chromatin Remodeling
Lindström, M. S. (2011) · Biochemistry Research International · doi:10.1155/2011/195209 · Cited by 307
Flying under the radar: the new wave of BCR–ABL inhibitors
Quintás-Cardama, A., Kantarjian, H., & Cortes, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2324 · Cited by 305
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
Jänne, P. A., Gray, N., & Settleman, J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2871 · Cited by 303
Fojo, T., Mailankody, S., & Lo, A. (2014) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2014.1570 · Cited by 303
Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition
Roskoski, R. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2012.11.007 · Cited by 303
Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non–Small Cell Lung Cancers
Lin, E., Li, L., Guan, Y., Soriano, R., Rivers, C. S., Mohan, S., Pandita, A., Tang, J., & Modrusan, Z. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0522 · Cited by 302
Menichincheri, M., Ardini, E., Magnaghi, P., Avanzi, N., Banfi, P., Bossi, R., Buffa, L., Canevari, G., Ceriani, L., Colombo, M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00064 · Cited by 299
Metadata
- Authors
- Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K. G., Shapiro, D. N., Saltman, D. L., & Look, A. T.
- Venue
- Science
- Published
- 1994-03-04
- Volume
- 263
- Issue
- 5151
- Pages
- 1281-1284
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2038586807
- Cited by
- 2,409
- References
- 17
- FWCI
- 35.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.